We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,370 hedge funds and large institutions have $109B invested in Bristol-Myers Squibb in 2021 Q2 according to their latest regulatory filings, with 146 funds opening new positions, 961 increasing their positions, 955 reducing their positions, and 112 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more call options, than puts

Call options by funds: $1.47B | Put options by funds: $1.06B

30% more first-time investments, than exits

New positions opened: 146 | Existing positions closed: 112

6% more capital invested

Capital invested by funds: $102B → $109B (+$6.21B)

3% more funds holding in top 10

Funds holding in top 10: 7072 (+2)

1% more repeat investments, than reductions

Existing positions increased: 961 | Existing positions reduced: 955

0.22% more ownership

Funds ownership: 73%73.22% (+0.22%)

0% more funds holding

Funds holding: 2,3692,370 (+1)

Holders
2,370
Holders Change
+1
Holders Change %
+0.04%
% of All Funds
41.25%
Holding in Top 10
72
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+2.86%
% of All Funds
1.25%
New
146
Increased
961
Reduced
955
Closed
112
Calls
$1.47B
Puts
$1.06B
Net Calls
+$411M
Net Calls Change
+$299M
Name Holding Trade Value Shares
Change
Change in
Stake
ONB
501
Old National Bancorp
Indiana
$7.84M +$316K +4,846 +4%
PMG
502
ProVise Management Group
Florida
$7.8M -$182K -2,796 -2%
RT
503
Rockland Trust
Massachusetts
$7.75M +$76.8K +1,178 +1%
KOCAA
504
Knights of Columbus Asset Advisors
Connecticut
$7.74M +$3.03M +46,504 +67%
H
505
Hexavest
Quebec, Canada
$7.71M -$7.9M -121,209 -51%
BAMF
506
BI Asset Management Fondsmaeglerselskab
Denmark
$7.66M +$1.09M +16,662 +17%
Balyasny Asset Management
507
Balyasny Asset Management
Illinois
$7.66M -$34.7M -532,898 -82%
AIM
508
Achmea Investment Management
Netherlands
$7.64M -$3.04M -46,695 -29%
Mercer Global Advisors
509
Mercer Global Advisors
Colorado
$7.63M +$614K +9,420 +9%
NCM
510
Novare Capital Management
North Carolina
$7.62M +$226K +3,471 +3%
TW
511
Transform Wealth
Colorado
$7.59M +$3.56M +54,523 +92%
PI
512
Parkside Investments
Illinois
$7.59M +$60.8K +933 +0.8%
DY
513
Dowling & Yahnke
California
$7.57M +$45.8K +702 +0.6%
JC
514
Jacobs & Co
California
$7.48M +$2.87K +44 +0%
GWM
515
Geneos Wealth Management
Colorado
$7.46M -$653K -10,016 -8%
GIA
516
Granite Investment Advisors
New Hampshire
$7.46M -$3.1M -47,501 -30%
GT
517
Glenview Trust
Kentucky
$7.39M -$182K -2,784 -2%
PCM
518
Parsons Capital Management
Rhode Island
$7.39M -$71.3K -1,094 -1%
GLLW
519
Graves Light Lenhart Wealth
Virginia
$7.36M +$3.04M +46,617 +73%
TSW
520
Thompson Siegel & Walmsley
Virginia
$7.32M
TBA
521
Tower Bridge Advisors
Pennsylvania
$7.32M -$761K -11,673 -10%
TCM
522
Twin Capital Management
Pennsylvania
$7.29M +$138K +2,120 +2%
GAAM
523
Guinness Atkinson Asset Management
California
$7.29M
QOP
524
Quinn Opportunity Partners
Virginia
$7.28M -$828K -12,702 -10%
WA
525
WealthTrust Axiom
Pennsylvania
$7.27M -$55.1K -845 -0.8%

BMY Hedge Fund Activity: Q2 2021 in Review

2,370 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2021, worth a combined $109B — up 6.1% from $102B a quarter earlier.

Buyers outnumbered sellers: 146 funds opened new BMY positions and 112 closed out — a net gain of 34 holders — while 961 added to existing stakes and 955 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $582M. The largest seller was Janus Henderson Group, cutting an estimated $444M.

  • 2,370 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2021, up from 2,369 in Q1 2021.
  • Funds reported $109B of Bristol-Myers Squibb stock for Q2 2021, up 6.1% quarter-over-quarter.
  • 146 funds opened new Bristol-Myers Squibb positions in Q2 2021 and 112 closed out, a net change of +34 holders.
  • The largest Bristol-Myers Squibb buyer in Q2 2021 was Fidelity Investments, an estimated $582M added.
  • The largest Bristol-Myers Squibb seller in Q2 2021 was Janus Henderson Group, an estimated $444M sold.

Based on aggregated 13F filings for Q2 2021.